Related Experiment Video

Updated: Mar 27, 2026

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

16.4K

[Regulators in access to anticancer drugs in Canada]

André Côté, Bernard Keating, Marc Parent

    Sante Publique (Vandoeuvre-Les-Nancy, France)
    |January 12, 2016
    PubMed

    Insights

    Provincial drug plans do not guarantee access to anticancer drugs (ACD). Regulatory differences significantly impact patient access, though less critical treatments are most affected.

    Area of Science:

    • Health Policy
    • Pharmaceutical Access
    • Canadian Healthcare System

    Context:

    • Provincial public health insurance systems in Canada provide drug coverage.
    • Previous studies highlighted variability in anticancer drug (ACD) access.
    • Concerns exist regarding equitable access to essential cancer treatments.

    Purpose:

    • To evaluate the impact of provincial regulatory frameworks on anticancer drug (ACD) accessibility.
    • To determine if public drug plan listing accurately reflects patient availability of ACDs.
    • To compare regulatory strategies across Canadian provinces influencing drug access.

    Summary:

    • This study analyzes provincial regulators affecting public health insurance access to anticancer drugs (ACD).
    • Regulators include conditions for public insurance access and third-party payer management strategies.
    • Variability in ACD access exists across provinces, primarily affecting non-essential therapies.

    Impact:

    • Highlights that drug listing alone is insufficient to ensure patient access to ACDs.
    • Reveals significant provincial disparities in regulatory approaches to drug management.
    • Suggests that policy interventions may be needed to improve equitable access to essential cancer drugs.

    More Related Videos

    Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

    Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

    Published on: February 6, 2015

    9.3K
    Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice08:57

    Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

    Published on: October 5, 2017

    11.6K

    Related Concept Videos

    Drug Regulation01:25

    Drug Regulation

    Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
    3.3K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.1K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    1.8K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    6.3K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.9K
    Drug Control Governance: Regulatory Bodies and Their Impact01:03

    Drug Control Governance: Regulatory Bodies and Their Impact

    Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
    648